Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
BCYC Stock Chart & Stats
$5.06
-$0.24(-1.59%)
At close: 4:00 PM EST
$5.06
-$0.24(-1.59%)
Day’s Range― - ―
52-Week Range$4.24 - $9.55
Previous CloseN/A
Volume92.63K
Average Volume (3M)496.53K
Market Cap
$366.26M
Enterprise Value-$244.89M
Total Cash (Recent Filing)$628.11M
Total Debt (Recent Filing)$17.52M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Apr 30, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding50,269,080
10 Day Avg. Volume343,762
30 Day Avg. Volume496,532
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)0.80
Price to Sales (P/S)6.76
P/FCF Ratio-1.94
Enterprise Value/Market Cap-0.67
Enterprise Value/Revenue-3.37
Enterprise Value/Gross Profit2.70
Enterprise Value/Ebitda1.04
Forecast
1Y Price Target
$14.33Price Target Upside183.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.18
Revenue Forecast (FY)$31.35M
Bulls Say, Bears Say
Bulls Say
Cash Runway And Financial StabilityAvailable cash reserves should fund operations for multiple years, supporting financial stability while development programs advance.
Cost Reduction And RestructuringWorkforce reductions and a major reorganization are expected to meaningfully reduce operating expenses and concentrate resources on the lead BT5528 program and the conjugate pipeline.
Lead Asset PrioritizationNuzefatide's emergence as the new lead asset for pancreatic cancer focuses development on a differentiated program whose forthcoming clinical data could clarify its potential and inform the development path.
Bears Say
Development Timeline DelaysConversion of the Duravelo program into a later-stage trial to gather additional data has delayed timelines and reduced near-term clinical catalysts.
Leadership And Clinical UncertaintyMajor leadership changes have raised questions about dose selection and the durability of the lead drug candidate, increasing uncertainty around clinical strategy.
Loss Of Lead Clinical AssetDiscontinuation of zele due to the absence of an accelerated approval path removes the former lead clinical asset and weakens near-term upside.
Bicycle Therapeutics News
BCYC FAQ
What was Bicycle Therapeutics Ltd’s price range in the past 12 months?
Bicycle Therapeutics Ltd lowest stock price was $4.24 and its highest was $9.55 in the past 12 months.
What is Bicycle Therapeutics Ltd’s market cap?
Bicycle Therapeutics Ltd’s market cap is $366.26M.
When is Bicycle Therapeutics Ltd’s upcoming earnings report date?
Bicycle Therapeutics Ltd’s upcoming earnings report date is Apr 30, 2026 which is in 14 days.
How were Bicycle Therapeutics Ltd’s earnings last quarter?
Bicycle Therapeutics Ltd released its earnings results on Mar 17, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.937 by $0.647.
Is Bicycle Therapeutics Ltd overvalued?
According to Wall Street analysts Bicycle Therapeutics Ltd’s price is currently Undervalued.
Does Bicycle Therapeutics Ltd pay dividends?
Bicycle Therapeutics Ltd does not currently pay dividends.
What is Bicycle Therapeutics Ltd’s EPS estimate?
Bicycle Therapeutics Ltd’s EPS estimate is -0.62.
How many shares outstanding does Bicycle Therapeutics Ltd have?
Bicycle Therapeutics Ltd has 50,269,080 shares outstanding.
What happened to Bicycle Therapeutics Ltd’s price movement after its last earnings report?
Bicycle Therapeutics Ltd reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.937. Following the earnings report the stock price went up 0.396%.
Which hedge fund is a major shareholder of Bicycle Therapeutics Ltd?
Currently, no hedge funds are holding shares in BCYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicycle Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.33 (183.20% Upside)
$14.33 (183.20% Upside)
Blogger Sentiment
Bearish
BCYC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 137.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $68.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.42%
12-Months-Change
Fundamentals
Return on Equity
-33.20%
Trailing 12-Months
Asset Growth
-25.01%
Trailing 12-Months
Company Description
Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
BCYC Stock 12 Month Forecast
Average Price Target
$14.33
▲(183.20% Upside)
Technical Analysis
Ownership Overview
23.12% Insiders
5.85% Mutual Funds
60.09% Other Institutional Investors
10.02% Public Companies and
Individual Investors